80 FR 32168 - Announcement of Requirements and Registration for “Up For A Challenge (U4C)-Stimulating Innovation in Breast Cancer Genetic Epidemiology”

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 108 (June 5, 2015)

Page Range		32168-32172
FR Document		2015-13816
The National Cancer Institute's (NCI) Division of Cancer Control and Population Sciences (DCCPS) announces that they are partnering with Sage Bionetworks to launch ``Up For A Challenge (U4C)-- Stimulating Innovation in Breast Cancer Genetic Epidemiology'' (the ``Challenge'') to encourage unique approaches to more fully decipher the genomic basis of breast cancer. Utilizing innovative approaches, the goal of this Challenge is to identify new genes or combinations of genes, genetic variants, or sets of genomic features involved in breast cancer susceptibility. In addition, the NCI aims to advance innovation in the field of genetic epidemiology by making data more widely available, increasing the amount and diversity of minds approaching a difficult scientific problem, and promoting broader collaborations. This Challenge is being launched under the America COMPETES Reauthorization Act of 2010.
Federal Register, Volume 80 Issue 108 (Friday, June 5, 2015)
[Federal Register Volume 80, Number 108 (Friday, June 5, 2015)]
[Notices]
[Pages 32168-32172]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-13816]



[[Page 32168]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Announcement of Requirements and Registration for ``Up For A 
Challenge (U4C)--Stimulating Innovation in Breast Cancer Genetic 
Epidemiology''


    Authority:  15 U.S.C. 3719.

    Award Approving Official: Douglas R. Lowy, Acting Director, 
National Cancer Institute.

SUMMARY: The National Cancer Institute's (NCI) Division of Cancer 
Control and Population Sciences (DCCPS) announces that they are 
partnering with Sage Bionetworks to launch ``Up For A Challenge (U4C)--
Stimulating Innovation in Breast Cancer Genetic Epidemiology'' (the 
``Challenge'') to encourage unique approaches to more fully decipher 
the genomic basis of breast cancer. Utilizing innovative approaches, 
the goal of this Challenge is to identify new genes or combinations of 
genes, genetic variants, or sets of genomic features involved in breast 
cancer susceptibility. In addition, the NCI aims to advance innovation 
in the field of genetic epidemiology by making data more widely 
available, increasing the amount and diversity of minds approaching a 
difficult scientific problem, and promoting broader collaborations. 
This Challenge is being launched under the America COMPETES 
Reauthorization Act of 2010.

DATES: 
Challenge Opens: June 15, 2015
Challenge Entries: Due January 15, 2016 (8 p.m. EST)
Challenge Judging: January 16, 2016-March 31, 2016
Winners Announced: April 16-20, 2016

    The NCI will announce any changes to the timeline by amending this 
Federal Register notice. This Challenge will be supported by Sage 
Bionetworks (https://www.synapse.org/upforachallenge) on behalf of the 
NCI.

ADDRESSES: To register for this Challenge, Challenge participants may 
access the registration on the Challenge Web site (https://www.synapse.org/upforachallenge). Access to this Web site may also be 
found by searching the www.challenge.gov site for ``Up For A 
Challenge.''

FOR FURTHER INFORMATION CONTACT: Elizabeth M. Gillanders, Ph.D., NCI, 
(240) 276-6764; Leah E. Mechanic, Ph.D., NCI, (240) 276-6847 or 
[email protected].

SUPPLEMENTARY INFORMATION: 

Subject of Challenge Competition

    In order to stimulate innovation, the National Cancer Institute's 
(NCI) Division of Cancer Control and Population Sciences (DCCPS) is 
launching a prize competition to inspire novel cross-disciplinary 
approaches to more fully decipher the genomic basis of breast cancer, 
called ``Up For A Challenge (U4C)--Stimulating Innovation in Breast 
Cancer Genetic Epidemiology'' (the ``Challenge'') using the America 
Creating Opportunities to Meaningfully Promote Excellence in 
Technology, Education, and Science (COMPETES) Reauthorization Act of 
2010.
    The goal of this Challenge is to use innovative approaches to 
identify novel pathways--including new genes or combinations of genes, 
genetic variants, or sets of genomic features--involved in breast 
cancer susceptibility in order to generate new biological hypotheses.
    To that end, several data sets have been gathered and will be made 
available for use in the Challenge; some of these will be released for 
the first time. In addition, Challenge participants will be free to use 
any other publicly available data sets (subject to compliance with 
applicable terms and conditions) for the purposes of developing and 
applying methods for identification of the novel pathways.
    Breast cancer is the most commonly occurring cancer, and the second 
most common cause of cancer deaths in women in the United States. An 
estimated 231,840 new cases of invasive breast cancer are expected to 
be diagnosed among women (2,350 in men) in the U.S. during 2015 with an 
estimated 40,730 deaths. Despite advances in breast cancer therapies, 
breast cancer remains a major public health burden. One approach to 
reduce overall occurrence and mortality from breast cancer is to 
develop ways of identifying women who are at increased risk for breast 
cancer.
    Epidemiologic studies suggest that genetic factors play a key role 
in determining who is at increased risk of developing breast cancer, as 
well as what type of cancer they develop. To date, genome-wide 
association studies (GWAS) have helped researchers identify more than 
90 common genetic variations. Although GWAS have greatly increased our 
understanding of the genetic components of breast cancer 
susceptibility, the results to date explain only a small proportion of 
the estimated genetic contribution to the risk of breast cancer. 
However, shifting the focus of analysis from individual genetic 
variants (also known as single nucleotide polymorphisms or SNPs) to 
pathways (i.e. combinations of genes, genetic variants, or sets of 
genomic features), could lead to the identification of novel gene sets 
involved in breast cancer risk.
    This Challenge provides an opportunity to examine the heritable 
contribution to racial disparities, by facilitating access to GWAS data 
sets from African American, Asian, European, and Latino women. African 
American women are known to have a lower incidence of breast cancer, 
but survival is lower for African American than for non-Hispanic white 
women at every stage of diagnosis. Meanwhile, Asian women have the 
lowest rates of breast cancer incidence and mortality compared with 
non-Hispanic white, African American, and Hispanic/Latino women. 
Findings from this Challenge may provide insights into some of these 
observed differences.
    As more fully described below, participants are invited to use 
innovative approaches to identify novel pathways--including new genes 
or combinations of genes, genetic variants, or sets of genomic 
features--involved in breast cancer susceptibility. Besides developing 
a better understanding of cancer risk assessment, the identification of 
breast cancer susceptibility genes holds promise for providing 
therapeutic targets for drug development.

Statutory Authority

    The NCI is authorized and established by Title IV, Part C, Subpart 
1 of the Public Health Service Act, 42 U.S.C. 285 to conduct and 
support research, training, health information dissemination, and other 
programs with respect to the cause, diagnosis, prevention, and 
treatment of cancer, rehabilitation from cancer, and the continuing 
care of cancer patients and the families of cancer patients. Through 
this Challenge, the NCI aims to advance innovation in the field of 
genetic epidemiology by making breast cancer genetic epidemiology data 
more widely available, increasing the number and diversity of 
researchers addressing a difficult scientific problem, and promoting 
broader collaborations. Ideally, this would result in insights into the 
genetic epidemiology of breast cancer.
    Official Rules:

Eligibility Rules for Participating in the Challenge and Winning

    1. To be eligible to win a prize under this Challenge, an 
individual or entity--
    a. Shall have registered to participate in the Challenge under the 
rules

[[Page 32169]]

promulgated by the National Cancer Institute (as published in this 
notice);
    b. Shall have complied with all the requirements under this 
section;
    c. In the case of a private entity, shall be incorporated in and 
maintain a primary place of business in the United States, and in the 
case of an individual, whether participating singly or in a team, shall 
be a citizen or permanent resident of the United States;
    d. May not be a Federal entity;
    e. May not be a Federal employee acting within the scope of his or 
her employment and further, in the case of HHS employees may not work 
on their Entries during assigned duty hours. Note: Federal ethical 
conduct rules may restrict or prohibit Federal employees from engaging 
in certain outside activities, so any Federal employee not excluded 
under the prior paragraph seeking to participate in this Challenge 
outside the scope of employment should consult his/her agency's ethics 
official prior to developing an Entry;
    f. May not be an employee of the NIH, a judge of the Challenge, or 
any other party involved with the design, production, execution, or 
distribution of the Challenge or the immediate family member of such a 
party (i.e., spouse, parent, step-parent, or step-child). Without 
limiting the generality of the foregoing, members of the Evaluation 
Panel which will score Entries and the NIH Judges, as well as their 
students are not eligible to participate in the Challenge.
    2. Federal grantees may not use Federal funds to develop Challenge 
Entries unless consistent with the purpose of their grant award and 
specifically requested to do so due to the Challenge design, and as 
announced in the Federal Register.
    3. Federal contractors may not use Federal funds from a contract to 
develop Challenge Entries or to fund efforts in support of a Challenge 
Entry.
    4. An individual, Team, or entity that is currently on the Excluded 
Parties List (https://www.epls.gov/) will not be selected as a Finalist 
or prize winner.
    5. Whether singly or as part of a team or entity, each individual 
participating in the Challenge must be 18 years of age or older.
    6. An individual shall not be deemed ineligible to win because the 
individual used Federal facilities or consulted with Federal employees 
during the Challenge provided that such facilities and/or employees, as 
applicable, are made available on an equitable basis to all individuals 
and Teams participating in the Challenge.
    7. Each individual (whether competing singly or in a team) or 
entity agrees to follow applicable local, State, and Federal laws and 
regulations.
    8. Each individual (whether participating singly or in a team) and 
entity participating in this Challenge must comply with all terms and 
conditions of these rules, and participation in this Challenge 
constitutes each such participant's full and unconditional agreement to 
abide by these rules, which may also be found on the Challenge Web site 
(https://www.synapse.org/upforachallenge). Winning is contingent upon 
fulfilling all requirements herein.
    All questions regarding the Challenge should be directed to Dr. 
Gillanders or Dr. Mechanic, identified above or by emailing 
[email protected] and answers will be posted and updated 
as necessary at (https://www.synapse.org/upforachallenge) under 
Frequently Asked Questions.

Registration Process for Participants

    To register for this Challenge, Challenge participants may access 
the registration on the Challenge Web site (https://www.synapse.org/upforachallenge). Access to this Web site may also be found by 
searching the www.challenge.gov site for ``Up For A Challenge.'' 
Individuals may participate in the Challenge as individuals or as 
Teams. Details about participating as a Team are provided below:
    1. After registration, you may participate alone or on a Team with 
other Challenge participants. To work on a Team, you may either create 
a new Team or join a pre-existing Team.
    2. There is no maximum Team size.
    3. All Teams must designate a Team Captain. Each individual member 
of a Team must be a registered participant in the Challenge.
    4. Individuals may participate on multiple Teams, and Challenge 
Teams may merge (requiring mutual agreement of Team Captains). 
Individuals are allowed to leave a Team to work alone or join another 
Team.

Data Access Process

    Once registered for the Challenge, participants must apply for 
controlled access to the designated Challenge genetic datasets 
following instructions on the Challenge Web site. Challenge 
participants may use any of these dbGaP datasets or any other datasets 
available to anyone (either publically available or available through 
controlled access) such as data from the Cancer Genome Atlas (TCGA) 
(http://cancergenome.nih.gov/) or the ENCyclopedia Of DNA Elements 
(ENCODE) project (http://www.genome.gov/encode/).
    Data will be requested through database of Genotypes and Phenotypes 
(dbGaP) application process. Details regarding the process for 
requesting data are provided on the Challenge Web site (https://www.synapse.org/upforachallenge). Data Access Requests will be reviewed 
by the appropriate NIH Data Access Committees (DAC) to ensure that the 
proposed project is consistent with any Data Use Limitations for the 
requested dataset(s). Note: That any scientific collaborators, 
including contractors, who are not at the same institution as the PI 
must submit their own DAR. Data cannot be shared with collaborators 
from other institutions until they have submitted an application (and 
explicitly named this collaborators) to use the dataset(s) from their 
institution(s) and have received approval. If Approved Users are 
provided access to NIH genomic datasets for inter-institutional 
collaborative research described in the research use statement of the 
DAR, and all members of the collaboration are also Approved Users 
through their home institution(s), data obtained through this DAR may 
be securely transmitted within the collaborative group.
    Challenge participants who obtain data from dbGaP should note that 
they are agreeing to the NIH Genomic Data User Code of Conduct (http://gds.nih.gov/pdf/Genomic_Data_User_Code_of_Conduct.pdf) and they are 
agreeing to the terms of specific Data Use Certificates for each 
individual dataset requested (The model Data Use Certificate can be 
found here--http://gds.nih.gov/pdf/Model_DUC.pdf). Note that individual 
datasets may have additional limitations in regards to use of the data. 
As the GWAS datasets obtained from dbGaP are considered controlled 
access data, individuals approved to use these data must abide by dbGaP 
security best practices in regards to the data (http://www.ncbi.nlm.nih.gov/projects/gap/pdf/dbgap_2b_security_procedures.pdf). If submitting a request to dbGaP for 
use of data for the Challenge, participants should be aware that the 
data requested should be used solely for the research purpose described 
in the Data Access Request, i.e., solely for the Challenge. New uses of 
these data outside this Challenge will require submission of a new Data 
Access Request.

Challenge Entries

    As used in this notice, ``Entry'' is the information submitted in 
the manner and format specified on the Up For A Challenge (U4C) Web 
site (https://www.synapse.org/upforachallenge). All Entries must be 
received by the

[[Page 32170]]

applicable deadline. Entries submitted after a posted Challenge 
deadline will not be considered.
    Entries may be submitted on behalf of a Team by any of its 
participants. It is up to each Team to organize its Entry(ies) and to 
follow the Challenge submission requirements. On submission of an 
Entry, Challenge participants must include the Team name under which 
they are submitting.
    All final Entries must be submitted through the Challenge Web site 
on Synapse, following Web site instructions and should provide 
necessary and sufficient detail and annotation for reproduction of the 
submitted results. Information accompanying each Entry should include:

1. Title of project
2. Name of Team
3. Names and field of expertise of Team members
4. List of new pair-wise collaborations on Team (defined as individuals 
not having published together in the past 5 years)
5. Information about how Team learned about the Challenge
6. Identification of datasets used (1 page)
7. A description of methods used to generate the findings (4 pages 
maximum)
8. Narrative which addresses the evaluation criteria (identification of 
novel findings, replication of findings, innovation of approach, 
evidence of novel biological hypothesis(es), and collaboration) (6 
pages maximum)
9. The corresponding source code so that the Challenge organizers can 
re-run and manually review and verify that the code affiliated with the 
top scoring Entries yield the submitted results.

    Only complete Entries, which follow application instructions, will 
be reviewed and eligible to win. Top performing Entries will be 
reviewed thoroughly. The NCI reserves the right to disqualify any 
Challenge participants in instances where cheating or other misconduct 
is identified. Details regarding the dispute resolution process are 
provided on the Challenge Web site (https://www.synapse.org/upforachallenge).

Warranties

    By submitting an Entry to the Challenge, Challenge participants 
represent and warrant that all information provided in their Entries 
and as a result of the Challenge registration process is true and 
complete, that Challenge participants have the right and authority to 
submit such Entry on their own behalf or on behalf of the persons and 
entities specified within the Entry, and that the Entry:
    1. Is the Challenge participant's or Team's (as applicable) own 
original work, or is used by permission with full and proper credit 
given within the Entry;
    2. Does not contain confidential information or trade secrets (the 
Team's or anyone else's);
    3. Does not violate or infringe upon the patent rights, industrial 
design rights, copyrights, trademarks, rights of privacy, publicity or 
other intellectual property or other rights of any person or entity;
    4. Does not contain malicious code, such as viruses, timebombs, 
cancelbots, worms, trojan horses or other potentially harmful programs 
or other material or information;
    5. Does not and will not violate any applicable law, statute, 
ordinance, rule or regulation; and
    6. Does not trigger any reporting or royalty obligation to any 
third party.

Amount of the Prize

    The grand prize Entry will be awarded up to $30,000. The second 
place Entry will be awarded a runner-up prize of up to $20,000. Prizes 
will be awarded by Sage Bionetworks. The top 5 Entries (grand prize, 
second place, and the next three runner-ups) as well as the People's 
Choice Award winner will be highlighted on the Challenge and DCCPS EGRP 
Web sites pending selection by the NCI Director. The top 5 Entries 
(grand prize, second place, and the next three runner-ups) as well as 
the People's Choice Award winner will be invited to prepare a 
manuscript for publication describing their approach and results with a 
goal of a special journal issue highlighting the Challenge. All 
Challenge participants will be acknowledged in the special issue of the 
journal, pending acceptance.
    The NIH reserves the right to cancel, suspend, and/or modify this 
Challenge at any time through amendment to this Federal Register 
notice. In addition, in the event the Challenge is modified, Challenge 
participants registered in the Challenge will be notified by email and 
provided with a copy of the amended Challenge rules and a listing of 
the changes that were made. Any participant who continues to 
participate in the Challenge following receipt of such a notice of 
amendment, will be deemed to have accepted any such amendment. If a 
participant does not wish to continue to participate in the Challenge 
pursuant to the Official Rules, as amended, such participant may 
terminate his/her/participation in the Challenge by not submitting 
additional Entries. The NIH reserves the right to not award any prizes 
if no Entries are deemed worthy.

Basis Upon Which Winner Will Be Selected

    Entries will be scored by the Challenge Evaluation Panel using the 
criteria listed below. After the Challenge Evaluation Panel provides 
final scores, the highest scoring applications will be evaluated for 
reproducibility by Sage Bionetworks' data scientists. In order to 
qualify for a Challenge prize, it must be possible for Sage 
Bionetworks' data scientists to reproduce Entry results within 1 month. 
The NCI Judges will review scores and reproduction by Sage and make 
recommendations to the NCI Director. The NCI Director will make the 
final selection of Entries for award.

Scoring Criteria (100 Points)

    1. Identification of Novel Findings (25 points)--Using breast 
cancer GWAS data sets available in dbGaP and/or any other publicly 
available data sets, Challenge participants must identify new genes or 
combinations of genes, genetic variants, or sets of genomic features 
associated with breast cancer susceptibility.
    a. The National Human Genome Research Institute's (NHGRI) Catalog 
of Published Genome Wide Association Studies (http://www.genome.gov/gwastudies/) or variants/loci identified in the following publications 
can be used to evaluate possible novel findings:
    i. Mavaddat et al., 2010, http://www.ncbi.nlm.nih.gov/pubmed/?term=20542480;
    ii. Ghoussani et al., 2013, http://www.ncbi.nlm.nih.gov/pubmed/?term=23973388;
    iii. Fachal and Dunning, 2015, http://www.ncbi.nlm.nih.gov/pubmed/?term=25727315)
    b. The scale for novelty for the Challenge Evaluation panel to use 
as a guide is provided:
    i. New variants in well-established high or moderate penetrance 
genes (e.g., BRCA1/BRCA2; ATM; PALB2) (low).
    ii. New variants in GWAS-identified genes or loci (med).
    iii. New combinations of variants which were previously identified 
(i.e., the combination or combined effect is new, but the variants were 
previously identified) (medium).
    iv. New genes or loci (high).
    v. New combinations of variants from genes or loci not identified 
previously

[[Page 32171]]

(i.e., the combination and some of the variants are new) (high).
    2. Replication of Findings (25 points)--Evidence of the validity of 
the proposed novel finding will be evaluated through replication.
    a. There are several different ways replication can be 
accomplished. These may include using data sets as testing and training 
data (or discovery in one data set and replication in another data set) 
or dividing the data into several portions and performing some type of 
cross-validation. The Challenge Evaluation panel will also be open to 
other innovative approaches for replication.
    i. The Challenge participant will need to select criteria for 
replication and provide a justification for the selected criteria. 
Using the criteria selected by the Challenge participant, the Challenge 
participant must demonstrate replication of findings.
    b. Note: Challenge participants should provide their criteria for 
replication in the narrative portion of their Challenge Entry.
    c. The adequacy of criteria selected by the Challenge participant 
and evidence for replication will be scored by the Challenge Evaluation 
Panel.
    3. Innovation of Approach (25 points)--Innovation and creativity of 
the submitted approach will be evaluated. Innovation will be defined as 
a new or significantly improved method. The submitted narrative must 
describe what is innovative about the approach, what this approach is 
building on, and why the approach is necessary or how it improves upon 
existing approaches. Some criteria for innovation include the 
following:
    a. Does the Entry seek to shift current paradigms by utilizing 
novel theoretical concepts, approaches, or methodologies?
    b. Are the concepts, approaches, or methods in the Entry novel to 
this field of research or novel in a broader sense?
    c. Does the Entry represent a refinement, improvement, or new 
application of theoretical concepts, approaches, or methodologies?
    4. Evidence of Novel Biological Hypothesis(es) (10 points)--
    a. Evaluation of this aspect of Challenge Entries will be based on 
whether findings (i.e., new genes or combinations of genes, genetic 
variants, or sets of genomic features) lead to novel biological 
hypotheses. A description of these hypotheses should be provided in the 
final project Entry.
    b. Novel biological hypotheses should be testable, either using 
computational or laboratory approaches. Evaluation will be based on the 
narrative description of the design of testable experiments, which 
could examine the novel biological hypothesis identified through these 
new genes or combinations of genes, genetic variants, or sets of 
genomic features associated with breast cancer. The format should 
mirror an outline of grant-specific aims.

    Note: The ``Evidence of Novel Biological Hypothesis(es)'' 
criteria (4) is distinct from the ``Identification of Novel 
Findings'' criteria (1). The ``Evidence of Novel Biological 
Hypothesis(es)'' criteria (4) is based on the narrative description 
of hypotheses generated from the findings and proposed follow up 
experiments. In contrast, the ``Identification of Novel Findings'' 
criteria (1) are the identification of new genes or combinations of 
genes, genetic variants, or sets of genomic features associated with 
breast cancer susceptibility.

    5. Collaboration (15 points)--Points will be awarded based on (a) 
the number of different fields represented on the Team; (b) the number 
of new collaborations represented on the Team (defined as individuals 
not having published together in the past 5 years); and (c) the number 
of individuals invited to participate in the Challenge by Team members 
resulting in Entries to the Challenge.

People's Choice Award

    In addition to the main prize, a People's Choice Award for the most 
interesting strategy may be given to the Entry that receives the most 
votes from the Challenge participants on the Challenge Web site. 
Details of how voting will take place will be posted on the Challenge 
Web site.

Additional Information

Intellectual Property

    By submitting an Entry, each Challenge participant warrants that he 
or she is the sole author and owner of any copyrightable works that the 
Entry comprises, that the works are wholly original with the Challenge 
participant (or is an improved version of an existing work that the 
Challenge participant has sufficient rights to use and improve), and 
that the Entry does not infringe any copyright or any other rights of 
any third party of which Challenge participant is aware.
    To receive an award, Challenge participants will not be required to 
transfer their exclusive intellectual property rights to the NIH. Each 
individual (whether competing singly or on a team) or entity retains 
title and full ownership in and to their Entry and expressly reserves 
all intellectual property rights (e.g., copyright) in their Entry. 
However, by participating in the Challenge each individual (whether 
competing singly or in a team) grants to the NCI and others acting on 
behalf of the NCI, a royalty-free non-exclusive worldwide license to 
use, copy for use, and display publicly all parts of the Entry for the 
purposes of the Challenge. This license may include posting or linking 
to the Entry on the official NCI Challenge Web site and making it 
available for research use by the public.
    When submitting source code as part of the Entry package, 
participants should provide it to the NCI under an open-source license 
of their choice. The license must permit the NCI contractor, Sage 
Bionetworks, to distribute the code to the public for non-commercial 
research and development use via the Synapse challenge platform. 
Participants may keep copyright to their code Entries. If participants 
do not provide information on licensing, participant's Entry shall be 
under the FreeBSD license.
    Challenge participants are free to discuss their Entry and the 
ideas or technologies that it contains with other parties and are free 
to contract with any third parties as long as they do not sign any 
agreement or undertake any obligation that conflicts with any agreement 
that they have entered into (i.e., with Team members) or do enter into 
regarding their Entry for the Challenge. For the purpose of clarity, 
Challenge participants acknowledge that the intent of the Challenge is 
to encourage people to collaborate and share ideas and innovations.
    By submitting an Entry, Challenge participants grant the NCI and 
the contractor Sage Bionetworks the limited rights set forth in these 
Official Rules. By submitting an Entry, each participant (whether 
competing singly or on a team) grants to the NCI and Sage Bionetworks 
the right to review their Entry and to have the NCI and their designees 
review the Entry.

Liability and Indemnification

    By participating in this Challenge, each Challenge participant 
(whether competing singly or on a Team) agrees to assume any and all 
risks and waive claims against the Federal government and its related 
entities, including Sage Bionetworks, the Challenge Evaluation Panel 
and the NCI Judges, except in the case of willful misconduct, for any 
injury, death, damage, or loss of property, revenue, or profits, 
whether direct, indirect, or consequential, arising from participation 
in this Challenge, whether the injury, death, damage, or loss arises 
through negligence or otherwise. By participating in this Challenge, 
each Challenge participant (whether competing singly or on a team)

[[Page 32172]]

agrees to indemnify the Federal government and the contractor Sage 
Bionetworks, against third party claims for damages arising from or 
related to Challenge activities.

Insurance

    Based on the subject matter of the Challenge, the type of work that 
it will possibly require, as well as an analysis of the likelihood of 
any claims for death, bodily injury, or property damage, or loss 
potentially resulting from competition participation, Challenge 
participants are not required to obtain liability insurance or 
demonstrate financial responsibility in order to participate in this 
Challenge.

Challenge Judges

Huann-Sheng Chen; Mathematical Statistician; Statistical Methodology 
and Applications Branch (SMAB); Surveillance Research Program (SRP); 
DCCPS; NCI
Eric J. Feuer; Ph.D.; Chief, SMAB; SRP; DCCPS; NCI
Leah Mechanic; Ph.D.; Program Director; Genomic Epidemiology Branch 
(GEB); Epidemiology and Genomics Research Program (EGRP); DCCPS; NCI
Elizabeth Gillanders; Ph.D.; Chief; GEB; EGRP; DCCPS; NCI
Carolyn M. Hutter, Ph.D.; Program Director; Division of Genomic 
Medicine; National Human Genome Research Institute
Margaret A. Tucker, M.D., Director, Human Genetics Program and Acting 
Chief, Laboratory of Translational Genomics; Division of Cancer 
Epidemiology and Genetics; NCI

    Dated: May 19, 2015.
Douglas R. Lowy,
Acting Director, National Cancer Institute.
[FR Doc. 2015-13816 Filed 6-4-15; 8:45 am]
 BILLING CODE 4140-01-P
32168 Federal Register / Vol. 80, No. 108 / Friday, June 5, 2015 / Notices

DEPARTMENT OF HEALTH AND Subject of Challenge Competition nucleotide polymorphisms or SNPs) to
HUMAN SERVICES In order to stimulate innovation, the pathways (i.e. combinations of genes,
National Cancer Institute’s (NCI) genetic variants, or sets of genomic
National Institutes of Health features), could lead to the
Division of Cancer Control and
Population Sciences (DCCPS) is identification of novel gene sets
Announcement of Requirements and involved in breast cancer risk.
Registration for ‘‘Up For A Challenge launching a prize competition to inspire
This Challenge provides an
(U4C)—Stimulating Innovation in novel cross-disciplinary approaches to
opportunity to examine the heritable
Breast Cancer Genetic Epidemiology’’ more fully decipher the genomic basis
contribution to racial disparities, by
of breast cancer, called ‘‘Up For A
facilitating access to GWAS data sets
Challenge (U4C)—Stimulating
Authority: 15 U.S.C. 3719. from African American, Asian,
Innovation in Breast Cancer Genetic
European, and Latino women. African
Award Approving Official: Douglas R. Epidemiology’’ (the ‘‘Challenge’’) using
American women are known to have a
Lowy, Acting Director, National Cancer the America Creating Opportunities to
lower incidence of breast cancer, but
Institute. Meaningfully Promote Excellence in
survival is lower for African American
SUMMARY: The National Cancer Technology, Education, and Science
than for non-Hispanic white women at
Institute’s (NCI) Division of Cancer (COMPETES) Reauthorization Act of
every stage of diagnosis. Meanwhile,
Control and Population Sciences 2010.
Asian women have the lowest rates of
(DCCPS) announces that they are The goal of this Challenge is to use
breast cancer incidence and mortality
partnering with Sage Bionetworks to innovative approaches to identify novel
compared with non-Hispanic white,
launch ‘‘Up For A Challenge (U4C)— pathways—including new genes or
African American, and Hispanic/Latino
Stimulating Innovation in Breast Cancer combinations of genes, genetic variants,
women. Findings from this Challenge
Genetic Epidemiology’’ (the or sets of genomic features—involved in
may provide insights into some of these
‘‘Challenge’’) to encourage unique breast cancer susceptibility in order to
observed differences.
approaches to more fully decipher the generate new biological hypotheses. As more fully described below,
genomic basis of breast cancer. Utilizing To that end, several data sets have
participants are invited to use
innovative approaches, the goal of this been gathered and will be made
innovative approaches to identify novel
Challenge is to identify new genes or available for use in the Challenge; some
pathways—including new genes or
combinations of genes, genetic variants, of these will be released for the first
combinations of genes, genetic variants,
or sets of genomic features involved in time. In addition, Challenge participants
or sets of genomic features—involved in
breast cancer susceptibility. In addition, will be free to use any other publicly
breast cancer susceptibility. Besides
the NCI aims to advance innovation in available data sets (subject to
developing a better understanding of
the field of genetic epidemiology by compliance with applicable terms and
cancer risk assessment, the
making data more widely available, conditions) for the purposes of
identification of breast cancer
increasing the amount and diversity of developing and applying methods for
susceptibility genes holds promise for
minds approaching a difficult scientific identification of the novel pathways.
providing therapeutic targets for drug
problem, and promoting broader Breast cancer is the most commonly
development.
collaborations. This Challenge is being occurring cancer, and the second most
launched under the America common cause of cancer deaths in Statutory Authority
COMPETES Reauthorization Act of women in the United States. An The NCI is authorized and established
2010. estimated 231,840 new cases of invasive by Title IV, Part C, Subpart 1 of the
breast cancer are expected to be Public Health Service Act, 42 U.S.C. 285
DATES:
diagnosed among women (2,350 in men) to conduct and support research,
Challenge Opens: June 15, 2015
Challenge Entries: Due January 15, 2016 in the U.S. during 2015 with an training, health information
(8 p.m. EST) estimated 40,730 deaths. Despite dissemination, and other programs with
Challenge Judging: January 16, 2016– advances in breast cancer therapies, respect to the cause, diagnosis,
March 31, 2016 breast cancer remains a major public prevention, and treatment of cancer,
Winners Announced: April 16–20, 2016 health burden. One approach to reduce rehabilitation from cancer, and the
The NCI will announce any changes overall occurrence and mortality from continuing care of cancer patients and
to the timeline by amending this breast cancer is to develop ways of the families of cancer patients. Through
Federal Register notice. This Challenge identifying women who are at increased this Challenge, the NCI aims to advance
will be supported by Sage Bionetworks risk for breast cancer. innovation in the field of genetic
(https://www.synapse.org/ Epidemiologic studies suggest that epidemiology by making breast cancer
upforachallenge) on behalf of the NCI. genetic factors play a key role in genetic epidemiology data more widely
determining who is at increased risk of available, increasing the number and
ADDRESSES: To register for this
developing breast cancer, as well as diversity of researchers addressing a
Challenge, Challenge participants may what type of cancer they develop. To
access the registration on the Challenge difficult scientific problem, and
date, genome-wide association studies promoting broader collaborations.
Web site (https://www.synapse.org/ (GWAS) have helped researchers
upforachallenge). Access to this Web Ideally, this would result in insights
identify more than 90 common genetic into the genetic epidemiology of breast
site may also be found by searching the variations. Although GWAS have greatly
asabaliauskas on DSK5VPTVN1PROD with NOTICES

www.challenge.gov site for ‘‘Up For A cancer.
increased our understanding of the Official Rules:
Challenge.’’ genetic components of breast cancer
FOR FURTHER INFORMATION CONTACT: susceptibility, the results to date explain Eligibility Rules for Participating in the
Elizabeth M. Gillanders, Ph.D., NCI, only a small proportion of the estimated Challenge and Winning
(240) 276–6764; Leah E. Mechanic, genetic contribution to the risk of breast 1. To be eligible to win a prize under
Ph.D., NCI, (240) 276–6847 or cancer. However, shifting the focus of this Challenge, an individual or entity—
NCIUpForAChallenge@mail.nih.gov. analysis from individual genetic a. Shall have registered to participate
SUPPLEMENTARY INFORMATION: variants (also known as single in the Challenge under the rules

VerDate Sep<11>2014 18:31 Jun 04, 2015 Jkt 235001 PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 E:\FR\FM\05JNN1.SGM 05JNN1
Federal Register / Vol. 80, No. 108 / Friday, June 5, 2015 / Notices 32169

promulgated by the National Cancer agrees to follow applicable local, State, Data will be requested through
Institute (as published in this notice); and Federal laws and regulations. database of Genotypes and Phenotypes
b. Shall have complied with all the 8. Each individual (whether (dbGaP) application process. Details
requirements under this section; participating singly or in a team) and regarding the process for requesting data
c. In the case of a private entity, shall entity participating in this Challenge are provided on the Challenge Web site
be incorporated in and maintain a must comply with all terms and (https://www.synapse.org/
primary place of business in the United conditions of these rules, and upforachallenge). Data Access Requests
States, and in the case of an individual, participation in this Challenge will be reviewed by the appropriate NIH
whether participating singly or in a constitutes each such participant’s full Data Access Committees (DAC) to
team, shall be a citizen or permanent and unconditional agreement to abide ensure that the proposed project is
resident of the United States; by these rules, which may also be found consistent with any Data Use
d. May not be a Federal entity; on the Challenge Web site (https:// Limitations for the requested dataset(s).
e. May not be a Federal employee www.synapse.org/upforachallenge). Note: That any scientific collaborators,
acting within the scope of his or her Winning is contingent upon fulfilling all including contractors, who are not at the
employment and further, in the case of requirements herein. same institution as the PI must submit
HHS employees may not work on their All questions regarding the Challenge their own DAR. Data cannot be shared
Entries during assigned duty hours. should be directed to Dr. Gillanders or with collaborators from other
Note: Federal ethical conduct rules may Dr. Mechanic, identified above or by institutions until they have submitted
restrict or prohibit Federal employees emailing NCIUpForAChallenge@ an application (and explicitly named
from engaging in certain outside mail.nih.gov and answers will be posted this collaborators) to use the dataset(s)
activities, so any Federal employee not and updated as necessary at (https:// from their institution(s) and have
excluded under the prior paragraph www.synapse.org/upforachallenge) received approval. If Approved Users
seeking to participate in this Challenge under Frequently Asked Questions. are provided access to NIH genomic
outside the scope of employment should datasets for inter-institutional
consult his/her agency’s ethics official Registration Process for Participants collaborative research described in the
prior to developing an Entry; To register for this Challenge, research use statement of the DAR, and
f. May not be an employee of the NIH, Challenge participants may access the all members of the collaboration are also
a judge of the Challenge, or any other registration on the Challenge Web site Approved Users through their home
party involved with the design, (https://www.synapse.org/ institution(s), data obtained through this
production, execution, or distribution of upforachallenge). Access to this Web DAR may be securely transmitted
the Challenge or the immediate family site may also be found by searching the within the collaborative group.
member of such a party (i.e., spouse, www.challenge.gov site for ‘‘Up For A Challenge participants who obtain
parent, step-parent, or step-child). Challenge.’’ Individuals may participate data from dbGaP should note that they
Without limiting the generality of the in the Challenge as individuals or as are agreeing to the NIH Genomic Data
foregoing, members of the Evaluation Teams. Details about participating as a User Code of Conduct (http://
Panel which will score Entries and the Team are provided below: gds.nih.gov/pdf/Genomic_Data_User_
NIH Judges, as well as their students are 1. After registration, you may Code_of_Conduct.pdf) and they are
not eligible to participate in the participate alone or on a Team with agreeing to the terms of specific Data
Challenge. other Challenge participants. To work Use Certificates for each individual
2. Federal grantees may not use on a Team, you may either create a new dataset requested (The model Data Use
Federal funds to develop Challenge Team or join a pre-existing Team. Certificate can be found here—http://
Entries unless consistent with the 2. There is no maximum Team size. gds.nih.gov/pdf/Model_DUC.pdf). Note
purpose of their grant award and 3. All Teams must designate a Team that individual datasets may have
specifically requested to do so due to Captain. Each individual member of a additional limitations in regards to use
the Challenge design, and as announced Team must be a registered participant in of the data. As the GWAS datasets
in the Federal Register. the Challenge. obtained from dbGaP are considered
3. Federal contractors may not use 4. Individuals may participate on controlled access data, individuals
Federal funds from a contract to develop multiple Teams, and Challenge Teams approved to use these data must abide
Challenge Entries or to fund efforts in may merge (requiring mutual agreement by dbGaP security best practices in
support of a Challenge Entry. of Team Captains). Individuals are regards to the data (http://
4. An individual, Team, or entity that allowed to leave a Team to work alone www.ncbi.nlm.nih.gov/projects/gap/
is currently on the Excluded Parties List or join another Team. pdf/dbgap_2b_security_procedures.pdf).
(https://www.epls.gov/) will not be If submitting a request to dbGaP for use
Data Access Process
selected as a Finalist or prize winner. of data for the Challenge, participants
5. Whether singly or as part of a team Once registered for the Challenge, should be aware that the data requested
or entity, each individual participating participants must apply for controlled should be used solely for the research
in the Challenge must be 18 years of age access to the designated Challenge purpose described in the Data Access
or older. genetic datasets following instructions Request, i.e., solely for the Challenge.
6. An individual shall not be deemed on the Challenge Web site. Challenge New uses of these data outside this
ineligible to win because the individual participants may use any of these dbGaP Challenge will require submission of a
used Federal facilities or consulted with datasets or any other datasets available
asabaliauskas on DSK5VPTVN1PROD with NOTICES

new Data Access Request.
Federal employees during the Challenge to anyone (either publically available or
provided that such facilities and/or available through controlled access) Challenge Entries
employees, as applicable, are made such as data from the Cancer Genome As used in this notice, ‘‘Entry’’ is the
available on an equitable basis to all Atlas (TCGA) (http:// information submitted in the manner
individuals and Teams participating in cancergenome.nih.gov/) or the and format specified on the Up For A
the Challenge. ENCyclopedia Of DNA Elements Challenge (U4C) Web site (https://
7. Each individual (whether (ENCODE) project (http:// www.synapse.org/upforachallenge). All
competing singly or in a team) or entity www.genome.gov/encode/). Entries must be received by the

VerDate Sep<11>2014 18:31 Jun 04, 2015 Jkt 235001 PO 00000 Frm 00088 Fmt 4703 Sfmt 4703 E:\FR\FM\05JNN1.SGM 05JNN1
32170 Federal Register / Vol. 80, No. 108 / Friday, June 5, 2015 / Notices

applicable deadline. Entries submitted complete, that Challenge participants Challenge pursuant to the Official Rules,
after a posted Challenge deadline will have the right and authority to submit as amended, such participant may
not be considered. such Entry on their own behalf or on terminate his/her/participation in the
Entries may be submitted on behalf of behalf of the persons and entities Challenge by not submitting additional
a Team by any of its participants. It is specified within the Entry, and that the Entries. The NIH reserves the right to
up to each Team to organize its Entry: not award any prizes if no Entries are
Entry(ies) and to follow the Challenge 1. Is the Challenge participant’s or deemed worthy.
submission requirements. On Team’s (as applicable) own original
work, or is used by permission with full Basis Upon Which Winner Will Be
submission of an Entry, Challenge
and proper credit given within the Selected
participants must include the Team
name under which they are submitting. Entry; Entries will be scored by the
All final Entries must be submitted 2. Does not contain confidential Challenge Evaluation Panel using the
through the Challenge Web site on information or trade secrets (the Team’s criteria listed below. After the Challenge
Synapse, following Web site or anyone else’s); Evaluation Panel provides final scores,
instructions and should provide 3. Does not violate or infringe upon the highest scoring applications will be
necessary and sufficient detail and the patent rights, industrial design evaluated for reproducibility by Sage
annotation for reproduction of the rights, copyrights, trademarks, rights of Bionetworks’ data scientists. In order to
submitted results. Information privacy, publicity or other intellectual qualify for a Challenge prize, it must be
accompanying each Entry should property or other rights of any person or possible for Sage Bionetworks’ data
include: entity; scientists to reproduce Entry results
4. Does not contain malicious code, within 1 month. The NCI Judges will
1. Title of project
such as viruses, timebombs, cancelbots, review scores and reproduction by Sage
2. Name of Team
worms, trojan horses or other and make recommendations to the NCI
3. Names and field of expertise of Team
potentially harmful programs or other Director. The NCI Director will make the
members
material or information; final selection of Entries for award.
4. List of new pair-wise collaborations 5. Does not and will not violate any
on Team (defined as individuals not applicable law, statute, ordinance, rule Scoring Criteria (100 Points)
having published together in the or regulation; and
past 5 years) 1. Identification of Novel Findings (25
6. Does not trigger any reporting or points)—Using breast cancer GWAS
5. Information about how Team learned royalty obligation to any third party.
about the Challenge data sets available in dbGaP and/or any
6. Identification of datasets used (1 Amount of the Prize other publicly available data sets,
page) The grand prize Entry will be Challenge participants must identify
7. A description of methods used to awarded up to $30,000. The second new genes or combinations of genes,
generate the findings (4 pages place Entry will be awarded a runner- genetic variants, or sets of genomic
maximum) up prize of up to $20,000. Prizes will be features associated with breast cancer
8. Narrative which addresses the awarded by Sage Bionetworks. The top susceptibility.
evaluation criteria (identification of 5 Entries (grand prize, second place, and a. The National Human Genome
novel findings, replication of the next three runner-ups) as well as the Research Institute’s (NHGRI) Catalog of
findings, innovation of approach, People’s Choice Award winner will be Published Genome Wide Association
evidence of novel biological highlighted on the Challenge and Studies (http://www.genome.gov/
hypothesis(es), and collaboration) DCCPS EGRP Web sites pending gwastudies/) or variants/loci identified
(6 pages maximum) selection by the NCI Director. The top in the following publications can be
9. The corresponding source code so 5 Entries (grand prize, second place, and used to evaluate possible novel findings:
that the Challenge organizers can the next three runner-ups) as well as the i. Mavaddat et al., 2010, http://
re-run and manually review and People’s Choice Award winner will be www.ncbi.nlm.nih.gov/pubmed/
verify that the code affiliated with invited to prepare a manuscript for ?term=20542480;
the top scoring Entries yield the publication describing their approach ii. Ghoussani et al., 2013, http://
submitted results. and results with a goal of a special www.ncbi.nlm.nih.gov/pubmed/
Only complete Entries, which follow journal issue highlighting the Challenge. ?term=23973388;
application instructions, will be All Challenge participants will be iii. Fachal and Dunning, 2015,
reviewed and eligible to win. Top acknowledged in the special issue of the http://www.ncbi.nlm.nih.gov/pubmed/
performing Entries will be reviewed journal, pending acceptance. ?term=25727315)
thoroughly. The NCI reserves the right The NIH reserves the right to cancel, b. The scale for novelty for the
to disqualify any Challenge participants suspend, and/or modify this Challenge Challenge Evaluation panel to use as a
in instances where cheating or other at any time through amendment to this guide is provided:
misconduct is identified. Details Federal Register notice. In addition, in i. New variants in well-established
regarding the dispute resolution process the event the Challenge is modified, high or moderate penetrance genes (e.g.,
are provided on the Challenge Web site Challenge participants registered in the BRCA1/BRCA2; ATM; PALB2) (low).
(https://www.synapse.org/ Challenge will be notified by email and ii. New variants in GWAS-identified
provided with a copy of the amended genes or loci (med).
asabaliauskas on DSK5VPTVN1PROD with NOTICES

upforachallenge).
Challenge rules and a listing of the iii. New combinations of variants
Warranties changes that were made. Any which were previously identified (i.e.,
By submitting an Entry to the participant who continues to participate the combination or combined effect is
Challenge, Challenge participants in the Challenge following receipt of new, but the variants were previously
represent and warrant that all such a notice of amendment, will be identified) (medium).
information provided in their Entries deemed to have accepted any such iv. New genes or loci (high).
and as a result of the Challenge amendment. If a participant does not v. New combinations of variants from
registration process is true and wish to continue to participate in the genes or loci not identified previously

VerDate Sep<11>2014 18:31 Jun 04, 2015 Jkt 235001 PO 00000 Frm 00089 Fmt 4703 Sfmt 4703 E:\FR\FM\05JNN1.SGM 05JNN1
32172 Federal Register / Vol. 80, No. 108 / Friday, June 5, 2015 / Notices

agrees to indemnify the Federal confidential trade secrets or commercial the discussions could disclose
government and the contractor Sage property such as patentable material, confidential trade secrets or commercial
Bionetworks, against third party claims and personal information concerning property such as patentable material,
for damages arising from or related to individuals associated with the grant and personal information concerning
Challenge activities. applications, the disclosure of which individuals associated with the grant
would constitute a clearly unwarranted applications, the disclosure of which
Insurance
invasion of personal privacy. would constitute a clearly unwarranted
Based on the subject matter of the Name of Committee: National Institute on invasion of personal privacy.
Challenge, the type of work that it will Deafness and Other Communication Name of Committee: Center for Scientific
possibly require, as well as an analysis Disorders Special Emphasis Panel; Clinical Review Special Emphasis Panel; Member
of the likelihood of any claims for death, Trial Review. Conflict: Skin and Autoimmune Diseases.
bodily injury, or property damage, or Date: June 24, 2015. Date: June 29–30, 2015.
loss potentially resulting from Time: 4:00 p.m. to 6:00 p.m. Time: 9:00 a.m. to 2:00 p.m.
competition participation, Challenge Agenda: To review and evaluate grant Agenda: To review and evaluate grant
participants are not required to obtain applications. applications.
Place: National Institutes of Health, Place: National Institutes of Health, 6701
liability insurance or demonstrate
Neuroscience Center, 6001 Executive Rockledge Drive, Bethesda, MD 20892
financial responsibility in order to Boulevard, Rockville, MD 20852 (Telephone (Virtual Meeting).
participate in this Challenge. Conference Call). Contact Person: Rajiv Kumar, Ph.D., Chief,
Challenge Judges Contact Person: Christine A. Livingston, MOSS IRG, Center for Scientific Review,
Ph.D., Scientific Review Officer, Division of National Institutes of Health, 6701 Rockledge
Huann-Sheng Chen; Mathematical Extramural Activities, National Institutes of Drive, Room 4216, MSC 7802, Bethesda, MD
Statistician; Statistical Methodology Health/NIDCD, 6001 Executive Blvd.—Room 20892, 301–435–1212, kumarra@csr.nih.gov.
and Applications Branch (SMAB); 8343, Bethesda, MD 20892, (301) 496–8683, Name of Committee: Center for Scientific
Surveillance Research Program (SRP); livingsc@mail.nih.gov. Review Special Emphasis Panel; RFA–RM–
DCCPS; NCI Name of Committee: National Institute on 14: Science of Behavior Change.
Eric J. Feuer; Ph.D.; Chief, SMAB; SRP; Deafness and Other Communication Date: June 29, 2015.
DCCPS; NCI Disorders Special Emphasis Panel; Clinical Time: 9:00 a.m. to 5:00 p.m.
Leah Mechanic; Ph.D.; Program Trials Review. Agenda: To review and evaluate grant
Date: July 23, 2015. applications.
Director; Genomic Epidemiology Place: National Institutes of Health, 6701
Time: 5:00 p.m. to 6:30 p.m.
Branch (GEB); Epidemiology and Agenda: To review and evaluate grant Rockledge Drive, Bethesda, MD 20892.
Genomics Research Program (EGRP); applications Contact Person: Dana Jeffrey Plude, Ph.D.,
DCCPS; NCI Place: National Institutes of Health, Scientific Review Officer, Center for
Elizabeth Gillanders; Ph.D.; Chief; GEB; Neuroscience Center, 6001 Executive Scientific Review, National Institutes of
EGRP; DCCPS; NCI Boulevard, Rockville, MD 20852 (Telephone Health, 6701 Rockledge Drive, Room 3176,
Carolyn M. Hutter, Ph.D.; Program Conference Call). MSC 7848, Bethesda, MD 20892, 301–435–
Director; Division of Genomic Contact Person: Christine A. Livingston, 2309, pluded@csr.nih.gov.
Medicine; National Human Genome Ph.D., Scientific Review Officer, Division of Name of Committee: Center for Scientific
Research Institute Extramural Activities, National Institutes of Review Special Emphasis Panel; PAR 13–
Health/NIDCD, 6001 Executive Blvd.—Room 109: Mechanistic Insights from Birth Cohorts.
Margaret A. Tucker, M.D., Director,
8343, Bethesda, MD 20892, (301) 496–8683, Date: June 30, 2015.
Human Genetics Program and Acting livingsc@mail.nih.gov. Time: 12:30 p.m. to 2:00 p.m.
Chief, Laboratory of Translational Agenda: To review and evaluate grant
(Catalogue of Federal Domestic Assistance
Genomics; Division of Cancer Program Nos. 93.173, Biological Research applications.
Epidemiology and Genetics; NCI Related to Deafness and Communicative Place: National Institutes of Health, 6701
Dated: May 19, 2015. Disorders, National Institutes of Health, HHS) Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Douglas R. Lowy, Dated: June 1, 2015. Contact Person: Ellen K. Schwartz, EDD,
Acting Director, National Cancer Institute. Melanie J. Gray, Scientific Review Officer, Center for
[FR Doc. 2015–13816 Filed 6–4–15; 8:45 am] Program Analyst, Office of Federal Advisory Scientific Review, National Institutes of
BILLING CODE 4140–01–P Committee Policy. Health, 6701 Rockledge Drive, Room 3144,
[FR Doc. 2015–13687 Filed 6–4–15; 8:45 am] Bethesda, MD 20892, 301–828–6146,
schwarel@mail.nih.gov.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND Name of Committee: Center for Scientific
HUMAN SERVICES Review Special Emphasis Panel; Small
Business: Dermatology, Rheumatology and
DEPARTMENT OF HEALTH AND Inflammation.
National Institutes of Health HUMAN SERVICES Date: July 1, 2015.
National Institute on Deafness and Time: 8:00 a.m. to 5:30 p.m.
National Institutes of Health Agenda: To review and evaluate grant
Other Communication Disorders;
applications.
Notice of Closed Meetings Center For Scientific Review; Notice of Place: Residence Inn Bethesda, 7335
Closed Meetings Wisconsin Avenue, Bethesda, MD 20814.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as Pursuant to section 10(d) of the Contact Person: Yanming Bi, Ph.D.,
asabaliauskas on DSK5VPTVN1PROD with NOTICES

Scientific Review Officer, Center for
amended (5 U.S.C. App.), notice is Federal Advisory Committee Act, as Scientific Review, National Institutes of
hereby given of the following meetings. amended (5 U.S.C. App.), notice is Health, 6701 Rockledge Drive, Room 4214,
The meetings will be closed to the hereby given of the following meetings. MSC 7814, Bethesda, MD 20892, 301–451–
public in accordance with the The meetings will be closed to the 0996, ybi@csr.nih.gov.
provisions set forth in sections public in accordance with the Name of Committee: Center for Scientific
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., provisions set forth in sections Review Special Emphasis Panel; Member
as amended. The grant applications and 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Conflict: AIDS and AIDS Related Research.
the discussions could disclose as amended. The grant applications and Date: July 7, 2015.

VerDate Sep<11>2014 18:31 Jun 04, 2015 Jkt 235001 PO 00000 Frm 00091 Fmt 4703 Sfmt 4703 E:\FR\FM\05JNN1.SGM 05JNN1
Document Created: 2015-12-15 15:20:12
Document Modified: 2015-12-15 15:20:12
Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		Challenge Opens: June 15, 2015 Challenge Entries: Due January 15, 2016 (8 p.m. EST) Challenge Judging: January 16, 2016-March 31, 2016 Winners Announced: April 16-20, 2016
Contact		Elizabeth M. Gillanders, Ph.D., NCI, (240) 276-6764; Leah E. Mechanic, Ph.D., NCI, (240) 276-6847 or [email protected]
FR Citation		80 FR 32168
80 FR 32168 - Announcement of Requirements and Registration for “Up For A Challenge (U4C)-Stimulating Innovation in Breast Cancer Genetic Epidemiology”

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 80, Issue 108 (June 5, 2015)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
